Cholesterol and Recurrent Events Trial (CARE): The Effect of Pravastatin on Coronary Events After Myocardial Infarction in Patients with Average Cholesterol Levels

Content Provider	Scilit
Author	Sacks, Frank M. Pfeffer, Marc A. Moye, Lemuel A. Hawkins, C. Morton Davis, Barry R. Rouleau, Jean L. Cole, Thomas G. Braunwald, Eugene
Copyright Year	1999
Description	Frank M. Sacks,1 Marc A. Pfeffer,2 Lemuel A. Moye,3 C. Morton Hawkins,3 Barry R. Davis,3 Jean L. Rouleau,4 Thomas G. Cole,5 and Eugene Braunwald2 for the CARE Trial Investigators 1Harvard School of Public Health, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts; 2Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; 3University of Texas School of Public Health, Houston, Texas; 4University Health Network and Mount Sinai Hospital, Toronto, Ontario, Canada; 5 Washington University, St. Louis, Missouri I. INTRODUCTION Plasma total and LDL cholesterol are predictors of initial or recurrent coronary heart disease (1-4), and lowering LDL cholesterol from elevated levels prevents recurrent coronary events (5-8). However, epidemiological studies show that the relationship between plasma cholesterol and coronary events is stronger in elevated than in average ranges (1-4). Prior to the CARE trial, it had not been clear whether coronary events can be prevented by cholesterol-lowering therapy in patients who did not have hypercholesterolemia. This is an important public health issue because the large majority of patients with coronary disease have total cholesterol and LDL levels in the average, not elevated, range (9-12), similar to that of the general population (13) (Fig. 1). The CARE trial specifically studied whether pravastatin, an inhibitor of HMG CoA reductase, could prevent recurrent coronary events and stroke in a typical postmyocardial infarction population with plasma total cholesterol <240 mg/dL (6.2 mmol/L), and LDL cholesterol levels 115-174 mg/dL (3.0-4.5 mmol/L). Book Name: Cholesterol-Lowering Therapy
Related Links	https://content.taylorfrancis.com/books/download?dac=C2006-0-16275-X&isbn=9780429092718&doi=10.1201/b15444-5&format=pdf
DOI	10.1201/b15444-5
Language	English
Publisher	Informa UK Limited
Publisher Date	1999-11-05
Access Restriction	Open
Subject Keyword	Book Name: Cholesterol-Lowering Therapy Cardiology and Cardiovascular Diseases Coronary Heart Disease Coronary Events
Content Type	Text
Resource Type	Chapter